CMS Open Payments · Program Year 2024
Blue Earth Diagnostics Limited
Blue Earth Diagnostics Limited reported $3,883,405.85 across General Payments, Research, and Ownership to 3,151 physicians and teaching hospitals across 3,519 transactions.
- $3.9M Top quartile payer
- All-tracks total
- 3,519 Top quartile volume
- Transactions
- 3,151 Top quartile reach
- Recipients
- −$116.3K
- General Payments vs PY2023
Blue Earth Diagnostics Limited reported $3,883,405.85 across all CMS Open Payments tracks (General + Research + Ownership) to 3,151 physicians and teaching hospitals in Program Year 2024 - ranking #313 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $324,055.51, averaging $1.2K per recipient.
How Blue Earth Diagnostics Limited's $3.9M all-tracks total breaks down
Blue Earth Diagnostics Limited's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
45/100
Total payments
F
46/100
Transaction volume
F
36/100
Physician reach
F
34/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer blue-earth-diagnostics-limited Blue Earth Diagnostics Limited
$3.9M · #313/1,925 · 0.0% industry · PY2024
- TOT $3.9M
- RANK #313
- SHARE 0.0%
- TXN 3,519
- RCP 3,151
- CAT 5
- GEN $324.1K
- ΔGEN −$116.3K
- TOP1 15.1%
- PY 2024
Volume peers
Nearest volume peer: Amicus Therapeutics, Inc. ($3.9M)
Blue Earth Diagnostics Limited sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Blue Earth Diagnostics Limited's CMS-reported General Payments decreased by $116.3K (−26.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BLUE EARTH DIAGNOSTICSPY2023: BLUE EARTH DIAGNOSTICSPY2024: Blue Earth Diagnostics Limited. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $440,343.42
- PY2024
- $324,055.51
What the Data Shows for Blue Earth Diagnostics Limited
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Blue Earth Diagnostics Limited, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
32 transactions worth $113.7K make "Consulting Fee" the top general-payment category in the 5-category breakdown below, 35.1% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Blue Earth Diagnostics Limited's 5-category general-payment breakdown at $113.7K, 35.1% of the reported total.
Blue Earth Diagnostics Limited reports 5 general-payment categories - the top three are Consulting Fee (35.1%), Food and Beverage (29.4%), and Honoraria (29.2%). The remaining 2 categories make up 6.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Blue Earth Diagnostics Limited divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $113.7K | 32 | 35.1% |
| Food and Beverage | $95.3K | 3,020 | 29.4% |
| Honoraria | $94.7K | 31 | 29.2% |
| Travel and Lodging | $18.4K | 66 | 5.7% |
| Compensation for Services Other Than Consulting | $2.0K | 2 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $124,173.35 (38.3%) of $324,055.51 in this company's General Payments records across 1,870 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Blue Earth Diagnostics Limited
The five named recipients with the highest reported General Payments from this company
- 1
Sean Collins
$48,821.78 across 50 reported transactions
- 2
Joshua E. Lantos
$28,760.00 across 2 reported transactions
- 3
Matthew Kay
$16,000.00 across 2 reported transactions
- 4
Alexandru Bageac
$15,680.00 across 3 reported transactions
- 5
Hossein Jadvar
$14,911.57 across 18 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Blue Earth Diagnostics Limited ranks #313 of 1,925 by total payments (top 16% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,336 of 1,838 by HHI (bottom 27% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Rhythm Pharmaceuticals, Inc. : $177.0K total payments, HHI 449
- Linvatec Corporation : $5.3M total payments, HHI 448
- Midsouth Orthopedics Inc. : $10.7K total payments, HHI 447
- Acclarent, Inc : $232.0K total payments, HHI 447
- Pinnacle Biologics, Inc : $70.6K total payments, HHI 445
- Gentleman Orthopedic Solutions : $20.0K total payments, HHI 445
- Blue Earth Diagnostics Limited (this company) : $324.1K total payments, HHI 444
- Trilliant Surgical LLC. : $844.6K total payments, HHI 443
- Innovasis Inc : $1.1M total payments, HHI 441
- Avadel CNS Pharmaceuticals, LLC : $1.5M total payments, HHI 441
- Intrinsic Therapeutics : $300.7K total payments, HHI 441
- Braeburn Inc. : $1.2M total payments, HHI 439
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Blue Earth Diagnostics Limited's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Blue Earth Diagnostics Limited.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Blue Earth Diagnostics Limited.
Showing 6 of 1,924 companies with CMS-reported payment data.
SmartHealth Inc
Harmony Biosciences LLC
Illumina, Inc.
Paragonix Technologies, Inc.
nView medical, Inc
Put this to use
Blue Earth Diagnostics Limited ranks #313 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Blue Earth Diagnostics Limited sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Blue Earth Diagnostics Limited. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.